Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label vatiquinone study in Friedreich ataxia
2022-002668-65Phase 3Active
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vatiquinone in Friedreich ataxia (FA), sponsored by PTC Therapeutics, Inc. Primary endpoint: Long-term safety of vatiquinone. Started Sep 2022; status: active.
02
Drugs
vatiquinone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2022-002668-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002668-65.